These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31166812)

  • 1. An alternative way - tyrosine kinase inhibitor (TKI) de-escalation - to discontinue TKIs in order to achieve treatment-free remission.
    Kunbaz A; Eskazan AE
    Expert Rev Hematol; 2019 Jul; 12(7):477-480. PubMed ID: 31166812
    [No Abstract]   [Full Text] [Related]  

  • 2. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
    Bhalla S; Tremblay D; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
    Caldemeyer L; Akard LP
    Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
    Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is There a Role for Dose Modification of TKI Therapy in CML?
    Copland M
    Curr Hematol Malig Rep; 2019 Aug; 14(4):337-345. PubMed ID: 31197525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The story of tyrosine kinase inhibitors discontinuation in clinical practice.
    Rousselot P
    Leuk Lymphoma; 2018 Dec; 59(12):2782-2791. PubMed ID: 29909726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia.
    Rabian F; Lengline E; Rea D
    Curr Hematol Malig Rep; 2019 Dec; 14(6):492-500. PubMed ID: 31760572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
    Kantarjian H; Cortes J
    J Clin Oncol; 2011 Apr; 29(12):1512-6. PubMed ID: 21422414
    [No Abstract]   [Full Text] [Related]  

  • 11. Circulating unconventional T-cell subsets during treatment with BCR-ABL1 tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia.
    Konuma T; Kohara C; Watanabe E; Mizukami M; Nagai E; Kato S; Takahashi S; Tojo A
    Eur J Haematol; 2019 Dec; 103(6):623-625. PubMed ID: 31512295
    [No Abstract]   [Full Text] [Related]  

  • 12. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
    Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
    Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
    [No Abstract]   [Full Text] [Related]  

  • 13. Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice.
    Clark RE
    Curr Hematol Malig Rep; 2019 Dec; 14(6):507-514. PubMed ID: 31701369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloid leukemia: Second-line drugs of choice.
    Gambacorti-Passerini C; Aroldi A; Cordani N; Piazza R
    Am J Hematol; 2016 Jan; 91(1):67-75. PubMed ID: 26588811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia.
    Engel NW; Constantin A; Fowlkes S; Assouline S
    J Oncol Pract; 2016 Jun; 12(6):592-4. PubMed ID: 27246687
    [No Abstract]   [Full Text] [Related]  

  • 16. How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.
    Rea D; Mahon FX
    Br J Haematol; 2018 Jan; 180(1):24-32. PubMed ID: 29048128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
    Ferrero D; Cerrano M; Crisà E; Aguzzi C; Giai V; Boccadoro M
    Br J Haematol; 2017 Feb; 176(4):669-671. PubMed ID: 26914729
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.
    Rinaldetti S; Pfirrmann M; Manz K; Guilhot J; Dietz C; Panagiotidis P; Spiess B; Seifarth W; Fabarius A; Müller M; Pagoni M; Dimou M; Dengler J; Waller CF; Brümmendorf TH; Herbst R; Burchert A; Janβen C; Goebeler ME; Jost PJ; Hanzel S; Schafhausen P; Prange-Krex G; Illmer T; Janzen V; Klausmann M; Eckert R; Büschel G; Kiani A; Hofmann WK; Mahon FX; Saussele S
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):266-271. PubMed ID: 29510895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of tyrosine kinase therapy in CML.
    Mahon FX
    Ann Hematol; 2015 Apr; 94 Suppl 2():S187-93. PubMed ID: 25814085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.